147627410 RANBAXY Company Profile

8/12/2019 147627410 RANBAXY Company Profile

1/20

INTRODUCTION TO RANBAXY

COMPANY PROFILE

A company empowered by one m!!on "#o p$ace #!e$% on #&e wor$d map' An

en#erpr!e prope$$ed by one %orce(#&a# !yner)*e! #! ener)e! #o c&ar#er +ne,p$ored

mar-e#!' Or)an*a#on! %+e$$ed by one dream(#o #ran!%orm compe##on n#o oppor#+n#y'.

Ranbaxy Laboratories Ltd. was incorporated in June 1961, in the name of M/S L!"#"#

R$%&$'( L$&)R$#)R"S L#* and it commenced its business in M$R+ 196-, in

technica and financia coaboration with an internationa company named L!#"# S!$,

M"L$%, "#$L(.

Ranbaxy Laboratories !t. Ltd. mer0ed with Leptit Ranbaxy Laboratories !t. Ltd.2 in

196- Ranbaxy and company aso mer0ed with this company in 1966. #he coaboration

arran0ement with M/S L!#"# was terminated in 19663 after which "ndian nationas ac4uired

the entire share capita of the company.

#herefore the word Leptit was remoed from the name of the company. #he name is

5nown as R$%&$'( L$&)R$#)R"S L"M"#*. "n 197 the company issued shares to the

0enera pubic and became a fuy fed0ed !8&L"+ L"M"#* +)M!$%(.

#oday, Ranbaxy has emer0ed as a Leadin0

!harmaceutica +ompany on the "ndian firmament,

with the second ar0est mar5et share and enoys an

eniabe reputation for its hi0h standard of ethics and

4uaity around its core stren0th of anti:infectie, it has

produced new brands in emer0in0 therapeutic areas

i5e cardioascuar, centra nerous system andnutritiona. Supportin0 this expansion, the company has inested in word cass manufacturin0

infrastructure that eera0es "ndia;s comparatie cost adanta0e and s5ied manpower, whie

deierin0 internationa 4uaity.


2/20

#he company;s drie for "nternationaism is 0uided by the we panned brand strate0y

that coers some of the word emer0in0 mar5ets i5e +hina, cis, +entra urope and Latin

$merica . "ts position today is in ea0ue of the #op #en !harmaceutica companies of three

word an decent ran5in0 as the eeenth ar0est company in the internationa 0enerics space is the

resoundin0 endorsement of its strate0ic mind.

"t is cear that for a on0 time, the dominant share of reenues of the company woud

continue to come from the eer expandin0 0oba 0enerics mar5et. ence the intent of Ranbaxy

mission is to achiee a sustained 0rowth rate throu0h the continuous pursuit of innoation phase

one trias for perasion, a compound for treatin0 prosthetic maes hae been competed. !hase 1

trias with cafrinast, an asthma compound are an important step towards research based aue

creation.

#his company aso had success with +ipofoxacine, an in0enious form, created throu0h

the noe dru0 deiery systems research. $s the demand of the bu5 dru0s inside the country and

abroad was increasin0y rapidy a new, pant was set up at #oansa near Ropar in 19=*$? of 8.S.$. #hispant has been approed by =*$ and this wi open up $merican and other newer mar5ets for

Ranbaxy;s products.

$t present Ranbaxy hae four pants for the manufacture of bu5 dru0s two at Mohai,

one at *ewas >M.!? $%* $nother at #oansa near R)!$R. $t present, Ranbaxy is the second

most "ndian company en0a0ed in the manufacturin0 of !harmaceuticas, &u5 *ru0s and =ine

+hemicas.

R$%&$'(;s ast ran0e of hi0hy pure aboratory rea0ent and chemicas enoy a pace

of pride in the mar5et. "# trends, has rebuit $s a step towards eera0in0 information for aue

creation usin0 its information bac5bone around an R! appication, aon0 the focus on

reen0ineerin0 seera business processes around the internet and has puttin0 pace business

soutions that chaen0e existin0 ways of doin0 &usiness. #he undyin0 spirit of the company;s


3/20


4/20

"n icensin0 and out icensin0, reationship with other important pharmaceutica entities,

expansion of manufacturin0 faciities both in "ndia and strate0ic oerseas ocations, reampin0

of or0aniEationa structures to cater to the wider and more dispersed span of operations, and

streaminin0 and standardiEin0 the business processes throu0hout the 0oba or0aniEation, are

other areas that receie focus and attention of mana0ement on priority.

M!!on

To become a Re!earc& ba!ed

In#erna#ona$ p&armace+#ca$ company.

/!on(6786

Ac&e3e !)n%can# b+!ne!! n

Propre#ary pre!crp#on prod+c#!

By 6786

9#& a !#ron) pre!ence n de3e$oped mar-e#!

A!pra#on!(6786

A!pre #o be a:; b$$on company

Become a Top ; )$oba$ )enerc! p$ayer

0)n%can# ncome %rom Propre#ary prod+c#!

OPERATIN2 Huan0Ehou +hina? Ltd.


5/20

H(!# G Ranbaxy 0ypt Ltd.

HRM$%( G &asics Hmb .

)%H I)%H G Ranbaxy >on0 Ion0? Ltd.

"%*"$ G Rexce pharmaceuticas Ltd.,

Sous pharmaceuticas Ltd.,

idyut #rae Serices td.

"RL$%* G Ranbaxy "reand Ltd.

M$L$(S"$ G Ranbaxy >Maaysia? Sdn. &hd.

%#RL$%*S G Ranbaxy !harmaceuticas &..

%"HR"$ G Ranbaxy %i0eria Ltd.

!$%$M$ G Ranbaxy !anama S$.

!)L$%* G Ranbaxy !oand Sp. Fo.

S)8# $=R"+$ G Ranbaxy >S$? >!ty.? Ltd.

#$"L$%* G 8nichem pharmaceuticas L#*.,

8nichem *istributors Ltd. !art,

Ranbaxy 8nichem +).Ltd.

8.I G Ranbaxy >8I? Ltd

8S$ G Ranbaxy pharmaceuticas "nc.

)hm Laboratories "nc.,


6/20

Ranbaxy Schein !harma, LL+

"#%$M G Ranbaxy ietnam +ompany Ltd.

ALLIED BU0INE00E0

Ranba,y Anma$ =ea$#&

#he $nima eath diision saw an encoura0in0 0rowth despite the preaiin0 poor

mar5et conditions. #he diision 0rew at twice the 0rowth rate recorded in the industry. )n the

basis of hain0 a ast dome satiated anima popuation, the iestoc5, poutry business and pets

business are amon0 the fastest 0rowin0 sectors in "ndia. $ ast infrastructure of eterinary

coe0es, a0ricutura institutes, technoo0ists and researchers are hepin0 farmers to source

heathy, cost effectie products. "n conunction with the present scenario, the $+ diision of

Ranbaxy Laboratories Limited has introduced seera atest 0eneration products.

Ranba,y Fne C&emca$! Lm#ed 4RFCL5

#he diision ran5ed Cth in the industry and captured 11@ mar5et share. R$%IM is

estabished as a powerfu brand, R=+LKs brand for its ran0e of Rea0ents is now synonymous

with exceence in rea0ents and fine chemicas in the country. #he focus of business remains on

deeopin0 extensie customer reations3 enhancin0 serice ees and enrichin0 the product mix


7/20

with the hep of a 4uaified and competent

mar5etin0 and saes team

Da)no!#c!

#he dia0nostics diision has

a00ressiey focused on mar5et expansion

actiities based on strate0y of reiabiity, 4uaity products and efficient serice. "ntroduction of

products in D!oint of +are; mar5ets has expanded mar5et presence and oer the next 1 - years

this se0ment wi see considerabe expansion in ine with word trends.

#he *ade &ehrin0 se0ment has increased its instaation base by 6B@ in eadin0 hospitasand aboratories. !ans are afoot for the introduction of more parameters for the D!oint of +are;

mar5et and the aunch of Specia +hemistries, a ran0e of dru0 assays, pus an entry into

automated microbioo0y in both the &ase and *ade &ehrin0 business areas.

#he company has aso witnessed si0nificant miestones in the area of %oe *ru0

*eiery Systems >%**S?. #he company has entered into strate0ic business arran0ements with

companies such as &ayer $H, Haxo:ecome, i:Liy etc. for production and co:mar5etin0

operations. Many innoatie deeopments hae been ta5in0 pace in recent times. #he


8/20

company;s research team is capabe of deeopin0 one %**S product eery 1- to 1< months.

$so, two new productsG Roetra:* and $tia:*, wi soon be aunched in "ndia.

"n order to expand and promote 0oba 0rowth, the company opened seera new mar5ets

durin0 the year, notaby in &raEi, where -A fiin0s were underta5en in a span of -:7 months.

#he company has panned to buid and protect inteectua property with the hep of "!+,

which addresses a matters pertainin0 to patents. +N$ superises the impementation of

standard operatin0 procedures >S)!? and ensures compiance to corporate 4uaity assurance

poicy in a technoo0ica operations of the or0aniEation. #he company is committed to inest

6@ of the saes in R and * by -BB7, of which @ of the expenditure wi be earmar5ed for

research on %ew *ru0 *iscoery and %oe *ru0 *eiery Systems. #here wi be continuous

emphasis on au0mentin0 R and * performance and productiity with adanced scientific and

technoo0ica toos.

/ALUE0 OF RANBAXY LABORATORIE0 LIMITED

1. $chiein0 customer satisfaction is fundamenta to their business.

-. !ractice di0nity and e4uity in reationships and proide opportunities for peope to reaiEe

their fu potentia.

7. nsure profitabe 0rowth and enhance weath of sharehoders.

C. =oster mutuay beneficia reationships with a their business partners.

A. Mana0e their operations with concern for safety and enironment.

6. &e a responsibe corporate citiEen.


9/20

OB


10/20

in pant desi0n, e4uipment seection, maintenance and operations. #he poicy see5s to

manufacture products safey and in an enironmentay responsibe manner.

#he impementation of the S !oicy is ensured by institutionaiEin0 a robust S

Mana0ement system, ade4uatey supported by we defined or0aniEationa structure.

$s a part of S processes at the corporate ee, besides ayin0 down 0uideines on

systems, poicy and trainin0, the corporate S office monitors compiance, maintains and

disseminates information on aws and re0uations. S performance reiew meetin0s are hed

on re0uar basis to monitor the pro0ress a0ainst a0reed S improement pans. +ose

cooperation between a units and indiiduas is the 5ey to maintainin0 hi0h standards of

enironment protection and safety in a the pants.

#he 5ey processes at ocation ee comprise of re0uar safety sureiance, inspections O

audits, !ermit to wor5 system for operationa / maintenance safety, =ire preention O protection

actiities, operation of the #!/"ncinerator, disposa actiities reated to haEardous wastes,

re0uar monitorin0 of the enironment internay and aso throu0h approed aboratories.

Monthy reports address S initiaties, compiance O arious records under the statutory

re4uirement, trainin0 of empoyees incudin0 contract empoyees on S awareness, interaction

with the residentia associations/nearby community etc., ceebration of %ationa safety day, fire

day, nironment day etc. for S awareness amon0 empoyees.

#he manufacturin0 faciities for bu5 dru0s and dosa0e forms compy with the strin0ent

re4uirements of Hood Manufacturin0 !ractices >HM!? and Hood Laboratory !ractices >HL!?

and are approed by "nternationa heath and re0uatory $0encies i5e =*$ : 8S$, M+$ 8I,

) etc. #hese practices and approas ensure that an effectie framewor5 is aways in pace,

not ony for manufacture of hi0h 4uaity products, but aso for effectie use of resources and

reduction of wastes as we as hi0h safety O hy0iene standards.

Ranbaxy has made si0nificant improements in process safety of the existin0

manufacturin0 faciities by proidin0 extensie instrumented safety protection systems. #he

intended safety features are incorporated in the basic desi0n of the new proects.


11/20

"nestments hae been made on process improements as we as effuent treatment pant

up:0radation usin0 the atest membrane based technoo0y, muti:effect therma eaporation

system and state:of:the:art "ncinerator. #hese inestments hae heped to reduce dischar0es of

contaminants into the enironment. ith the faciities instaed at #oansa for recycin0 of the

treated effuent, the site has achieed the status of Eero dischar0e site2.

#he +ompany aso en0a0es with the concerned authorities and industry in deisin0

responsibe aws, re0uations and standards and thus ma5in0 safety, occupationa heath O

enironmenta information and expertise aaiabe to its empoyees and the community at ar0e.

Ranbaxy has made S concerns and practices a necessary factor in appraisin0 its empoyee

performance.

#he +ompany aso accords a ery hi0h priority to hy0iene monitorin0 at wor5 pace and

heath assessment of a empoyees at site. #he pant and processes are continuousy up0raded to

improe hy0iene and heath standards. %ecessary trainin0 is imparted to the empoyees to

enhance their awareness towards heath reated matters.

Safety 5nowed0e of the empoyees is constanty updated throu0h arious externa and

in:house trainin0 pro0rams, incudin0 specia trainin0 pro0rams by oerseas experts O

consutants.

Moin0 up the aue chain, the company identified +onsumer eathcare as its new

business area in the year -BB1. Ranbaxy Hoba +onsumer eathcare >RH+? was aunched in

)ctober -BB- with a portfoio of C switch brandsG Reita, !epfiE, Hesdyp O Haric !ears. Since

these brands were aready popuar amon0st consumers and represented the eadin0 common

aiment cate0ories i5e MS >itamins O Mineras Suppement?, this portfoio was carefuy

created for the introduction of RH+ to the "ndian mar5et. Subse4uenty in -BBC, RH+

aunched its first herba ran0e of products throu0h %ew $0e erbas >%$? with products

offerin0 remedy in cate0ories of +ou0h O +od >)esan )i O +ou0h Syrups? and $ppetite

Stimuant >at ase?.

/ARIOU0 DI/I0ION0 OF RANBAXY LABORATORIE0 LTD'

8' C&emca$ D3!on


12/20

6' Da)no!#c D3!on

' 0#an care D3!on

' C+rrada D3!on

;' In#erna#ona$ D3!on

' P&armace+#ca$ D3!on

' Tec&nca$ D3!on

' Corpora#e D3!on

' Anma$ =ea$#& Care D3!on

DI/I0ION0 IN /ARIOU0 2EO2RAP=ICAL AREA0

8' Inda and Mdd$e Ea!#

6' E+rope> CI0 and A%rca

' A!a Pac%c and La#n Amerca

' Nor#& Amerca


13/20

-BBB Ranbaxy fies "%* $ppication for $sthma Moecue: R&xC67tradin0 under the %ame of

&asics? in Hermany.

Ranbaxy forays into &raEi, the ar0est pharmaceutica mar5et in

South $merica and achiees 0oba saes of 8.S. P -.A miion in

this mar5et.

-BB1 Ranbaxy too5 a si0nificant step forward in ietnam by initiatin0

the Settin0 up of a new manufacturin0 faciity with an inestment

of 8.S. P 1B miion.

Ranbaxy achieed a turnoer of 8.S. P AB- miion for the year

-BB- and moed coser to achiein0 a tar0et of 1 biion doar by

-BBC.

-BB- Receies approa from =*$ to mar5et MidaEoam ydrochoride

Syrup - M0 base/ m. Ranbaxy receies and approa from =*$ to

manufacture and mar5et +efpodoxime !roxeti for )ra

Suspension, Lisinopri Q ydrochorothiaEide #abets 8s,

#eraEosin ydrochoride +apsues and $moxciin )ra

suspension 8S!.eradin0 the company;s entry into the "ndian

)#+ mar5et.

-BB7 Ranbaxy receied the economic times award for corporate

exceence:for the company for year.ranbaxy si0ned an a0reementtoac4uire R!H>aentis? S$ aon0 with its fuy owned

subsidiary,)!" S$RL,in france

-BBC Ranbaxy aunched its first ran0e of herba proects.


14/20

-BBA AcG+!#on o% add#ona$ !#a-e n Ranba,y Farmace+#ca

L#da'> Bra*$ Ranbaxy announced the ac4uisition of &e:#abs

!harmaceuticas >!ty? Limited

-BB< $c4uired by the Japanese 0iant, the P9.6- biion *aiichi San5yo,

ran5ed %o. 7 in Japan

BRIEF INTRO OF RANBAXY PLANT0 IN INDIA

"n the chemica diision, arious bu5 dru0s are manufactured. #he chemica diision had

three units in !unab. )ne is ocated at #oansa, two are ocated at Mohai and one unit is ocated

at *ewas near "ndore in Madhya !radesh, where +iprofoxacine is manufactured. "n the pant of

the chemica diision, arious dru0s i5e $ntibiotics, $nti:maaria, $ntibacteria and $nti:ucer

are manufactured. )ne of the oder pants of Ranbaxy was cosed after the accident in June

-BB7.the second one is sti wor5in0.

#he 1991, the #oansa pant started functionin0 in 199- and the *ewas pant started

functionin0 in 1999. arious pant heads independenty mana0e a these pants.

"n each unit, separate faciities with respect to the manufacture of dru0s, aon0 with their

manufacturin0 areas hae been proided. #his is re4uired to reduce the chances of any cross

contamination under the dru0 aws and to compy with 0ood manufacturin0 practices.

$t Mohai pant, separate boc5s hae been proided for the preparation of each dru0 .#he

#oansa, Mohai and *ewas pants are panned in such a way that their system, faciities,

manufacturin0 practices and standards meet the re4uirements of =*$. Mohai !ant aso mainy

in the manufacturin0 of $ctie !harmaceutica "n0redients >$!"?. #he !ant is diided into two

pant areas $< and $9.

=E /ARIOU0 DEPARTMENT0


15/20

=+man Re!o+rce Depar#men#

#he basic function of the human resource department in the modern corporate word is

5nowed0e mana0ement. #he R department stries to maintain cohesieness amon0

empoyees. "t aso ensures interdepartmenta cooperation in achiein0 tar0ets. #he appraisa

system is aso ta5en care by this department. #he R department dees deep into the

empoyee;s psyche to anayEe the posities and ne0aties of each empoyee, so that a proper

system of dee0ation and / or empowerment can be eoed.

Fnance Depar#men#

#he finance department ta5es care of the re0uar financia needs of the company it

ensures proper aocation of funds and ta5es care of the wor5in0 capita re4uirements. "t erifiescapita raised by different departments and sends them for approa to the hi0her authorities.

0#ore! Depar#men#

#he function of this department is to proide ade4uate and proper stora0e and

preseration of arious items to meet the demand of arious other departments by proper issues

and maintainin0 accounts of consumption. "t aso 5eeps a trac5 of stoc5 accumuation and

abnorma consumption.

Erec#on and Fabrca#on Depar#men#

$s the name su00ests, this department identifies new proects and heps in erectin0 them.

#his department aso underta5es maor modifications of e4uipment.

ERP Depar#men#

R! department heps to inte0rate the entire enterprise startin0 from the suppier to the

customer, coerin0 financia and human resources. #his wi enabe the enterprise to increase


16/20

productiity by reducin0 costs. "t aso ensures a sin0e soution to the information needs of the

whoe or0aniEation.

Prod+c#on Depar#men#

$s a part of their on0oin0 commitment to produce hi:tech 4uaity dru0s and pharmaceuticas that

ta5e care of the specific needs of mar5ets around the word, Ranbaxy Laboratories Limited has

increased the inestment in the production department. "t is the most important department of the

company and has the foowin0 obectiesG

1. "mproin0 oume of production.

-. Reducin0 reection rate.

7. Maintainin0 rewor5 rate.

En)neern) Depar#men#

#his department underta5es buidin0, construction and maintenance. Maintainin0 serice

faciities such as water, 0as, heatin0, entiation, air conditionin0, paintin0 and pumbin0 are

some of the other areas deat by this department. #his department aso heps in maintainin0

eectrica e4uipments such as 0enerators, transformers, teephone system and eectricainstaation.

P+rc&a!e Depar#men#

#he purchase department proides materia to the factory without which the whees of

machines cannot moe. #he arious functions performed by this department incudeG Securin0

0ood endor performance, incudin0 prompt deieries of suppies of acceptabe 4uaities.

1. #o deeop satisfactory sources of suppy and maintainin0 0ood reationships with the

suppiers.

-. #o pay reasonaby ow prices.


17/20

H+a$#y Con#ro$H+a$#y A!!+rance Depar#men#

#he purpose of N+ O N$ departments is to ensure that the desired 4uaity standard is

achieed. "t aso ensures that the processin0 or fabrication of materia conforms to the specific

characteristics seected, to assure that the resutin0 product wi in fact perform its intended

function.

PRODUCT RE/IE9

Ranbaxy;s therapeutic width coers fie of the top six cate0ories incudin0 $nti:

infectie, Hastrointestina, %utritionas, +ardioascuar, +entra %erous System, Respiratory,

*ermatoo0ica and others. hie anti:infectie contribute A6@ of the tota saes, Ranbaxy;s

other brands i5e Simotin and Storas in the cardioascuar se0ment, Serift in +%S and Reitaand Riconia in %utritionas, are on their way to success in mutipe mar5ets.

*urin0 Jan : *ec -BBB, amon0st the top products of Ranbaxy, Sporidex >+ephaexin? was

the %umber 1 brand, cosey foowed by +ifran >+iprofoxacin?.

An# ( In%ec#3e!

$nti: infectie has been the main drier of Ranbaxy;s saes. #he important brands in this

cate0ory are +ifran >+iprofoxacin?, Sporidex >+iphaexin?, nhancin >$moxyca?, +rixan

>+arithromycin?, ercef >+efacor?, )framax >+eftriaxone?, +epodem >+efpodoxime !roxeti?,

Fanocin >)foxacin?, +eroxim >+efuroxime $xeti?, and Loxof >Leofoxacin?.

+ifran >+iprofoxacin? is the 5ey brand in the anti: infectie portfoio, with estimated

saes of 8S P 7- Mn, currenty bein0 mar5eted in 1A countries. *eeopment of +iprofoxacin

once a day has been an important andmar5 achieed by Ranbaxy. #he product has been icensed

to &ayer. +ifran continues to be a dominant payer in the 4uinoones mar5et in "ndia, +hina and

Russia.

Sporidex is another eadin0 brand in Ranbaxy;s product portfoio with wordwide annua

saes of 8S P 7A Mn. "t is aaiabe in ei0ht different dosa0e forms incudin0 capsues, dry


18/20

powder for suspension, redimix, dispersibe tabets, paediatric drops, soft 0eatin capsues, sachet

and adanced formuation for twice:daiy administration. "t is currenty mar5eted in 1A countries.

"n "ndia, Sporidex is the eadin0 brand with a mar5et share of 76@ of the +ephaexin se0ment.

Iefor is aaiabe in seen different dosa0e forms and is the third:ar0est sein0 brand

for Ranbaxy wordwide. #he dosa0e forms ist incudes capsues, dry syrup, modified reease

tabets, dispersibe tabets, drops and redimix.

nhancin is expected to be the eadin0 product in Ranbaxy;s product portfoio with

estimated saes of 8S P CA Mn by the year -BBA. #he product wi be roed out to about -B

important mar5ets durin0 this period.

Fanocin, with approximate saes of 8S P 1B Mn, is the seenth:ar0est contributor toRanbaxy;s tota saes.

+epodem is currenty aaiabe in three different countries outside "ndia, and wi be

roed out to 17 different countries in the near future.

Cardo3a!c+$ar!

+ardioascuar is proected to be the second:best cate0ory for Ranbaxy. Statins hae

been the 5ey driers for this se0ment. #he sae of Simastatin has 0rown substantiay in the past

few years, a trend that is i5ey to continue in the future. "n "ndia, Simotin >Simastatin? is the

mar5et eader in the choestero reducer se0ment. $nother eadin0 brand in this cate0ory is

Storas >$torastatin?. Storas has been one of the fastest:eer to enter the top:7BB brands ist of

the "ndian pharma industry. )ther 0oba cardioascuar brands are +oance >Losartan? and

+asot >+aredio?.

Cen#ra$ Ner3o+! 0y!#em

#he +entra %erous Se0ment is one of the important focus areas identified by Ranbaxy,

with Serift bein0 the 5ey brand. "n "ndia, Serift is number 1 amon0st Sertraine brands. %ew

product introductions wi be driers of 0rowth in this cate0ory.

2a!#ron#e!#na$


19/20

+urrenty, 0astrointestina dru0s are the second:ar0est cate0ory for Ranbaxy. #he 5ey

brands in this cate0ory incude istac and Romesac. #he current annua saes of Ranitidine are

estimated to be around 8S P 16 Mn and the product is mar5eted in more than -B countries.

R&e+ma#o$o)ca$!

#he first 0eneration +ox:- inhibitors principay drie wordwide 0rowth in

rheumatoo0y. #his cate0ory is estimated to 0row exponentiay for Ranbaxy, with brands i5e

+eecoxib. #his year, Rofibax >Rofecoxib? introduced in "ndia, has estabished itsef as a eader

in the +ox:- inhibitor cate0ory and has oerta5en a +eecoxib brands. "t has been identified as

a 5ey Hoba brand for the future.

N+#r#ona$!

%utritionas hae been a maor contributor to Ranbaxy;s saes. #wo of the important

products in this cate0ory are Reita and Riconia. ith annua saes estimated at about 8S P 1B

Mn, Reita contributes a si0nificant share of tota saes. "t is a eadin0 brand in "ndia and has

done exceedin0y we in some parts of the word as an )#+ product.

Derma#o$o)ca$!

#he dermatoo0y cate0ory is mainy drien by "ndia re0ion and is i5ey to show a 0ood

0rowth pattern in the future. Some of the 5ey brands doin0 we in this se0ment are MobiEox,

Sierex, Moisturex, etc.


20/20

147627410 RANBAXY Company Profile

Documents

Transcript of 147627410 RANBAXY Company Profile